DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio

Wednesday, 27 April 2016

Veronica (Novotny) Diermayr

 Veronica (Novotny) Diermayr; PhD

Veronica (Novotny) Diermayr; PhD

Head of Development at D3 (Drug Discovery and Development), BMSI



* Broad understanding of cancer biology, holistically applied to the discovery and development of drugs and biomarkers.
Experienced in preclinical and early clinical development in oncology & infectious diseases and immunology for small molecule and biologics

* Proven ability to contribute to preclinical and Phase 1/2 development, biomarker development and validation, medical rationale & positioning, study protocol development and Investigator's Brochure writing

* Excellent scientific, leadership, personal management and organizational skills

* Knowledgeable and trained in GLP and GCP and a very keen interest in the medical aspects of oncology and immunology

* Keen, enthusiasticand emphathetic team worker with a “can-do” attitude, good mentoring skills and proven leadership qualities

Specialties: Key areas of expertise: biomarker development, pre-clinical and early clinical development (Phase 0 – 2) in the areas of oncology, immunology, infectious diseases; in-depth and hands-on knowledge of animal efficacy studies, pharmacodynamics and PK/PD models, in vitro kinase assays, molecular biology, signal transduction, protein production, clinical research, project management, scientific writing


Head of Development

D3 (Drug Discovery and Development), BMSI
– Present (1 year 1 month)Singapore

Head of Project Management

D3 (Drug Discovery and Development), BMSI
– Present (4 years 3 months)Singapore
As a Project Manager and biomarker expert in D3 we are currently doing the pre-clinical development of an anti-neoplastic small molecule (wnt signaling inhibitor) for solid tumors targeting to obtain an IND by Sept. 2014.
We have successfully completed the a Phase I, first-in man, healthy volunteer, multi-center study testing a VLP-vaccine.

Our small- molecule kinase inhibitors for the treatment of a subset of chronic myeloid leukemia patients are just entering preclinical development. Furthermore D3 is in the process of in-licensing two exciting first-in class oncology compounds.
In the non-oncology area we are involved in the preclinical development of MSC exosomes for small indications for PoC.

Team Leader

S*BIO Pte Ltd
(6 years)Singapore
- Project management & leadership for biomarker group and animal pharmacology group
- Biology leader for an early stage drug discovery project
- Coordinate research with other teams
- Manage CROs for various outsourced studies
- Coordinate work with clinical study teams to validate and apply biomarkers for clinical trials
- Operationally support the application of validated biomarkers for clinical trials
- Organize, report and communicate study outcome to the project team
- Write & submit scientific publications as corresponding author
- Deliver & present data packages & scientific rationale for filings (IND, FDA, reports etc)
- present to senior management/international community
- perform as an effective leader who supervises and coaches research associates

Senior Reserach Fellow

Institute for Molecular and Cell Biology (IMCB), Singapore
(5 years 3 months)Singapore
Molecular Biology studies in the field of Oncology

Research Fellow

Novartis Research Institute, Vienna, Austria
(3 years 1 month)Vienna
Mast Cells & Dendritic cells, Sphingosine Kinase pathways, compound screening for novel inhibitors
(Open)1 organization

Research fellow, Vienna Medical University, Institute of Immunology

VIRC - Vienna International Reserach Cooperation, Institute of Immunology (Prof. Knapp)
(1 year)
studied the active signal transduction pathways in patients with Wiskott-Aldrich Syndrome using EBV transformed B-cells


Haematological Society Austria



Full Member


Phase 1 and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939,in patients with refractory solid malignancies

Annals of Oncology
March 8, 2011

Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of SB939, an Oral Histone Deacetylase Inhibitor (HDACi), in Patients with Advanced Solid Tumors

British Journal of Cancer
February 1, 2011

SB939, a novel potent and orally active histone deacetylase inhibitor with high exposure and efficacy in mouse models of colorectal cancer

Molecular Cancer Therapeutics
March 2, 2010

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer(Link)

Molecular Cancer Therapeutics
December 27, 2012
2 authors
  • Veronica Diermayr; PhD
    Veronica Diermayr; PhD
    Head of Development at D3 (Drug Discovery and Development), BMSI
  • Stefan Hart
    Stefan Hart
    Director, New Ventures Singapore/SEA/India at Johnson & Johnson Innovation Center Asia Pacific

Modulation of the interleukin-6 receptor subunit glycoprotein 130 complex and its signaling by LMO4 interaction

Journal of Biological Chemistry
January 27, 2005

The LIM/homeodomain protein Islet1 recruits Janus tyrosine kinases and signal transducer and activator of transcription 3 and stimulates their activities

Molecular Biology of the Cell
January 19, 2005

A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation

The Journal of Biological Chemistry
May 13, 2003

GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction

March 17, 2003

Protein kinase C  associates with the interleukin-6 receptor subunit gp130 via Stat3 and enhances Stat3-gp130 interaction

Journal of Biological Chemistry

Novel mode of interference with NF-AT regulation in T-cells by the bacterial metabolite n-butyrate

Journal of Biological Chemistry

Glycosphingolipid-induced relocation of Lyn and Syk into detergent resistant membranes results in mast cell activation

Journal of Immunology

The balance between sphingosine and sphingosine-1-phosphate is decisive for mast cell activation after FcRI triggering

The Journal of Experimental Medicine

TNF and IL-5 gene induction in IgE plus antigen stimulated mast cells require common and distinct signaling pathways

International Archives of Allergy and Immunology

Nrf1 in a complex with fos B, c-jun, junD, and ATF2 forms the AP1 component at the TNF promoter in stimulated mast cells.

Nucleic Acid Research

Common and distinct signaling pathways mediate the induction of TNF and IL-5 in IgE plus antigen-stimulated mast cells

The Journal of Immunology

A novel splice variant of the transcription factor Nrf1 interacts with the TNF promoter and stimulates transcription

Nucleic Acid Research

The ultrastructure of the cuticle of Nematoda II. The cephalic cuticle of Stilbonematinae (Adenophoraea, Desmodoridae)



Medizinische Universität Wien

Ph.D.,, Immunology (Prof. Knapp)

Lectures in immunology, FACS analyses, focus on hematology-oncology,
Activities and Societies: Austrian Society of Haematology

Universität Wien

Ph.D., Masters of Science, Cell/ Cellular and Molecular Biology

Wollongong High School



1 comment:

  1. Great post! I am see the great contents and step by step read really nice information.I am gather this concepts and more information. It's helpful for me my friend. Also great blog here with all of the valuable information you have.
    PTE Coaching in Chennai